...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical principles and practice: international journal of the Kuwait University, Health Science Centre >Incremental Diagnostic Value and Impact on Patient Management of Somatostatin Receptor Scintigraphy with Indium-111-Pentetreotide in Gastroenteropancreatic Neuroendocrine Tumors
【24h】

Incremental Diagnostic Value and Impact on Patient Management of Somatostatin Receptor Scintigraphy with Indium-111-Pentetreotide in Gastroenteropancreatic Neuroendocrine Tumors

机译：肠胃胰腺神经内分泌肿瘤对111生长抑素的生长抑素受体显像的诊断价值及其对患者管理的影响

获取原文
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: To evaluate the efficacy of somatostatin analog scintigraphy with indium-111-pentetreotide and its overall impact on management in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET). Subjects and Methods: Twenty-two consecutive patients with a proven or clinically suspected GEP-NET with or without proven metastases were imaged at 24 and 48 h after injection of 111In-pentetreotide. The scintigraphic findings were compared with results from conventional imaging methods. The final diagnosis was based on histopathological and surgical findings and complementary radiology. Results: Somatostatin receptor-positive lesions were found in 20 of the patients, whereas conventional methods were positive in 18 patients. Additionally, 13 new tumor sites were discovered by somatostatin receptor scintigraphy in 5 patients (liver: 6; chest: 2; bone: 1; abdomen: 4). The surgical therapeutic strategy was changed in 7 patients (32%). Conclusions: Our data reinforced that scintigraphy with 111In-pentetreotide represents the imaging modality of choice in the initial evaluation of GEP-NET. It is highly accurate and can identify clinically unsuspected lesions and optimize the overall staging. It also guides optimal therapy choice and most importantly identifies patients with inoperable or metastatic disease who might be candidates for high-dose targeted therapy.
机译：目的：评价生长抑素类似物闪烁体扫描与111-戊喷肽的疗效及其对胃肠道胰腺神经内分泌肿瘤（GEP-NET）治疗的总体影响。研究对象和方法：在注射 111 戊喷肽后的24和48小时内，对22例连续的已证实或临床怀疑有GEP-NET的患者进行了影像学检查。将闪烁显像结果与常规成像方法的结果进行比较。最终诊断是基于组织病理学和手术结果以及补充放射学。结果：生长激素抑制素受体阳性病变在20例患者中发现，而常规方法在18例患者中为阳性。此外，通过生长抑素受体闪烁扫描在5例患者中发现了13个新的肿瘤部位（肝脏：6;胸部：2;骨骼：1;腹部：4）。 7例患者（32％）改变了手术治疗策略。结论：我们的数据进一步证明，在GEP-NET的初始评估中，采用 111 In-pentetreotide闪烁显像可以代表选择的成像方式。它具有很高的准确性，可以识别出临床上未曾怀疑的病变并优化整体分期。它还指导最佳疗法的选择，最重要的是确定无法手术或转移性疾病的患者，这些患者可能是大剂量靶向治疗的候选对象。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号